Analyst Reco. CureVac N.V. Deutsche Boerse AG

Equities

Market Closed - Deutsche Boerse AG Other stock markets 17:05:21 31/05/2024 BST			5-day change	1st Jan Change
3.58 ^EUR	+5.29%		+3.23%	-6.77%

05-28	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT
05-28	CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	CI

CUREVAC : Significant cash drain in the Q1	05-23
CUREVAC : A missed opportunity	05-02
UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	04-26	MT
Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	04-25	MT
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10	12-22	MT
CUREVAC : An untrimmed pipeline becomes costly	11-29
CUREVAC : Unchanged cash drain	11-28
CUREVAC : A missed opportunity	21/08/23
CUREVAC : Higher losses expected in future	25/07/23
CUREVAC : Some glimpse of positive pipeline developments	21/06/23
SVB Securities Initiates CureVac at Outperform With $13 Price Target	08/06/23	MT
CUREVAC : Runway prolonged	30/05/23
CUREVAC : One big point despite many misses	02/05/23
JMP Securities Adjusts Price Target on CureVac to $24 From $34, Maintains Outperform Rating	26/04/23	MT
CUREVAC : Everything hangs on the decision of the new CEO	16/03/23
UBS Upgrades CureVac to Buy From Neutral, Adjusts Price Target to $18 From $8	19/01/23	MT
CUREVAC : UBS raises its recommendation to Buy	19/01/23	ZD
Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup	09/01/23	DJ
Jefferies Upgrades CureVac to Buy From Hold	09/01/23	MT
CUREVAC : Berenberg reaffirms its Buy rating	06/01/23	ZD

No results for this search

CUREVAC : Significant cash drain in the Q1

May 23, 2024 at 08:49 pm